InMed Pharmaceuticals (NASDAQ:INM) Posts Earnings Results

by · The Cerbat Gem

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) issued its earnings results on Thursday. The company reported ($0.44) EPS for the quarter, Zacks reports. InMed Pharmaceuticals had a negative net margin of 171.13% and a negative return on equity of 92.47%.

InMed Pharmaceuticals Stock Performance

Shares of NASDAQ:INM traded down $0.11 during mid-day trading on Friday, reaching $1.60. The company had a trading volume of 135,393 shares, compared to its average volume of 74,730. InMed Pharmaceuticals has a one year low of $1.56 and a one year high of $8.27. The company has a current ratio of 6.99, a quick ratio of 6.47 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $2.12 and its 200-day moving average price is $2.50. The firm has a market cap of $4.48 million, a price-to-earnings ratio of -0.13 and a beta of 0.29.

Wall Street Analyst Weigh In

INM has been the subject of a number of research reports. Wall Street Zen raised InMed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of InMed Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Get Our Latest Stock Report on InMed Pharmaceuticals

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.

See Also